Sonde Health recognized for achievements in vocal biomarker technology
BOSTON–(BUSINESS WIRE)–#vocalbiomarker—Sonde Health, a leading vocal biomarker technology platform, has been named to CB Insights’ third annual Digital Health 150, which showcases the 150 most promising private digital health companies in the world. Recipients were chosen based on several factors, including data submitted by the companies, company business models and momentum in the market, and Mosaic scores, CB Insights’ proprietary algorithm that measures the overall health and growth potential of private companies.
“This recognition is a testament to the growth Sonde has experienced in 2021, from expanding our product portfolio with the launch of our Mental Fitness product to partnering with Qualcomm to integrate our technology into their Snapdragon™ 8 Gen 1 and 778G 5G mobile platforms,” said David Liu, CEO of Sonde Health. “In 2022 we will continue to form new strategic partnerships to accelerate and scale the delivery of vocal biomarker technology to an even broader user base.”
The 2021 Digital Health 150 cohort has raised roughly $14.9B in aggregate funding across 522 deals since 2016, and includes startups at various investment stages of development, from early-stage to well-funded unicorns. Companies this year include startups working on data integration & analytics, hybrid virtual / in-person care, digital therapeutics, clinical intelligence, and more.
“This year’s Digital Health 150 is one of our most expansive yet, spotlighting 16 categories including virtual care, clinical trials tech, and workflow automation, as well as adding new categories such as home health tech and computer-aided imaging,” said Brian Lee, SVP of CB Insights’ Intelligence Unit. “Last year’s class has seen more than 20 exits, raised an additional $18.6B in aggregate funding, and announced over 250 partnerships since being recognized, and we’re excited to see the future success of this year’s winners.”
2021 Digital Health 150 Investment Highlights:
- Unicorns: 17 of the 150 companies (11%) are valued at or above $1B as of their latest funding rounds.
- Funding trends: In 2021 year-to-date (YTD), these 150 private companies have raised $9.2B in equity funding across 153 deals (as of 11/19/21).
- Mega-rounds: Since 2020, there have been 39 mega-round ($100M+) equity investments to this year’s Digital Health 150, with 31 (79%) of them taking place in 2021 YTD.
- Global representation: 23% of the 2021 Digital Health 150 are based outside the US. After the US, the UK is home to the most Digital Health 150 companies (9), followed by India (4). This year’s winners are based in 18 countries, including China, Israel, Nigeria, Germany, Argentina, and New Zealand.
- Top VC investor: General Catalyst is the most active investor in this year’s Digital Health 150 companies, having invested in 39 deals since 2016.
The Digital Health 150 Companies (in alphabetical order):
- 1upHealth
- 54gene
- Ablacon
- Acclinate
- accuRx
- ACTIV Surgical
- Ada Health
- Adyn
- AKASA
- Allara Health
- Alma
- Altoida
- AppliedVR
- Astarte Medical
- b.well
- Better Health
- Binx Health
- BioIntelliSense
- Birdie
- BrightInsight
- Brightline
- c2i Genomics
- Caption Health
- Caresyntax
- Carrum Health
- Castor EDC
- Cedar
- Centaur Labs
- Circulo
- Cityblock Health
- Clarify Health
- Cleerly
- Cleo
- ClosedLoop.ai
- Cohere Health
- Commure
- Congenica
- Curebase
- DeepScribe
- DiA Imaging Analysis
- eko
- Eleanor Health
- Element5
- Elemy
- Elligo Health Research
- Elucid
- Emocha Mobile Health
- Empathy
- Equip
- Exo
- Field Intelligence
- Folx Health
- Genome Medical
- GYANT
- Happify
- Hawthorne Effect
- Headway
- Health Gorilla
- Hello Heart
- Hinge Health
- Honor Technology
- Innovaccer
- Iterative Scopes
- ixLayer
- Jasper Health
- Kaia Health
- Koa Health
- Komodo Health
- League
- LeanTaaS
- LetsGetChecked
- Limbix
- LinkedCare
- Loop Health
- Lumen
- Lunit
- Mahana Therapeutics
- Medable
- Medically Home Group
- Medly Pharmacy
- MedRhythms
- Memora Health
- Meru Health
- Monogram Health
- mPharma
- NeuroFlow
- Nile AI
- NOCD
- Nym
- ObvioHealth
- Olive
- Ophelia
- Osana
- Oshi Health
- Osmind
- Overjet
- Oviva
- Oxehealth
- Paige.AI
- Papa
- PathAI
- Perspectum
- Phable
- Plume
- Pristyn Care
- Proximie
- Quit Genius
- Qure.ai
- RadAI
- Reify Health
- Rendever
- Ribbon Health
- Rightway
- See-Mode Technologies
- Seer Medical
- Sempre Health
- Seqster
- Shukun Technology
- Sidekick Health
- Soda Health
- Somatus
- Sonde Health
- Spring Health
- Stellar Health
- Stork Club
- Strata Oncology
- Sweetch Health
- Sympatient
- Syntegra
- Tendo Systems
- Theator
- Tia
- Tomorrow Health
- Transcarent
- Tripp
- Truepill
- Twin Health
- uLab Systems
- Ultromics
- Unite Us
- Unmind
- Vesta Healthcare
- Vital
- Vocalis Health
- Vori Health
- Wellsheet
- Wheel
- Woebot Health
- Xealth
- Zeen Health
About CB Insights
CB Insights builds software that enables the world’s best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit www.cbinsights.com.
About Sonde Health
Sonde Health has developed an enterprise vocal biomarker development platform that enables any enterprise to create novel health detection and monitoring products from voice. Sonde scales data collection, feature development, model creation and clinical validation in collaboration with its partners and customers. Leveraging over 1 million voice samples from 80,000+ individuals, Sonde uses advanced audio signal processing and machine learning to sense and analyze subtle vocal changes due to changes in a person’s physiology to provide key insights into health and wellbeing.
Contacts
CB Insights Press:
[email protected]
Sonde Health Press:
Denise DiMeglio
Gregory FCA
[email protected]
610-228-2102
If you enjoyed this article and want to receive more valuable industry content like this, click here to sign up for our digital newsletters!
